Pill Identifier App

NanoViricides Inc. Posts Photos Showing Rapid Response of Animals to Treatment with EKC Eye Drug Candidate

WEST HAVEN, Conn.--(BUSINESS WIRE)--Jun 9, 2008 - NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it has posted photos on its website which show the rapid response to treatment using the Company's nanoviricide drug candidate against Epidemic Kerato-Conjunctivitis (EKC) (http://www.nanoviricides.com/action_small_EKC_2008-06-09.html).

The eyes treated with the best nanoviricide drug candidate showed virtual absence of inflammation and significant decrease in the redness of the conjunctiva, i.e. the area surrounding the cornea. The eyes treated with a negative control eye wash solution show the usual redness and inflammation caused by the disease. Substantial improvement occurred within only 2.5 days after treatment in this preliminary study. Further biological analyses are in progress.

"This may be the very first demonstration of a rapid and clear clinical response against adenoviral EKC," said Anil R. Diwan, PhD, President of the Company, adding, "The robustness of the nanoviricides technology is also now amply evident. We have demonstrated industry-leading efficacies in our very first experiments against widely varying viral diseases such as common influenza, H5N1 bird flu, rabies, Ebola, and now adenoviral EKC."

"We plan to evaluate this broad-spectrum eye-drop formulation against other viruses causing inflammation of the eye such as herpes simplex virus (HSV)," said Eugene Seymour, MD, MPH, CEO of the Company.

While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for these classes of eye disease is expected to be of the order of several billion dollars annually.

Dr. Seymour discussed these results and the broad-spectrum nature of nanoviricides drug candidates at the NSTI Nanotech 2008 conference in Boston last week.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

Contact

NanoViricides, Inc.
Amanda Schuon. 310-550-7200
info@nanoviricides.com

Posted: June 2008

View comments

Hide
(web5)